The stock of Korro Bio Inc (KRRO) has gone down by -0.90% for the week, with a 65.96% rise in the past month and a 64.04% rise in the past quarter. The volatility ratio for the week is 15.81%, and the volatility levels for the past 30 days are 16.59% for KRRO. The simple moving average for the past 20 days is -4.29% for KRRO’s stock, with a 25.76% simple moving average for the past 200 days.
Is It Worth Investing in Korro Bio Inc (NASDAQ: KRRO) Right Now?
The stock has a 36-month beta value of 3.74. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for KRRO is 5.92M, and at present, short sellers hold a 4.43% of that float. On November 13, 2024, the average trading volume of KRRO was 112.33K shares.
KRRO) stock’s latest price update
Korro Bio Inc (NASDAQ: KRRO)’s stock price has dropped by -11.37 in relation to previous closing price of 73.50. Nevertheless, the company has seen a loss of -0.90% in its stock price over the last five trading days. globenewswire.com reported 2024-11-04 that -Regulatory filing of Phase 1/2 clinical study for Alpha-1 Antitrypsin Deficiency (AATD) submitted to Australian Bellberry Human Research Ethics Committee (HREC)
Analysts’ Opinion of KRRO
Many brokerage firms have already submitted their reports for KRRO stocks, with Raymond James repeating the rating for KRRO by listing it as a “Strong Buy.” The predicted price for KRRO in the upcoming period, according to Raymond James is $153 based on the research report published on October 21, 2024 of the current year 2024.
William Blair, on the other hand, stated in their research note that they expect to see KRRO reach a price target of $180. The rating they have provided for KRRO stocks is “Outperform” according to the report published on August 14th, 2024.
H.C. Wainwright gave a rating of “Buy” to KRRO, setting the target price at $115 in the report published on March 28th of the current year.
KRRO Trading at 31.55% from the 50-Day Moving Average
After a stumble in the market that brought KRRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.53% of loss for the given period.
Volatility was left at 16.59%, however, over the last 30 days, the volatility rate increased by 15.81%, as shares surge +63.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +46.81% upper at present.
During the last 5 trading sessions, KRRO fell by -0.90%, which changed the moving average for the period of 200-days by +31.41% in comparison to the 20-day moving average, which settled at $68.06. In addition, Korro Bio Inc saw 35.91% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KRRO starting from Agarwal Vineet, who sale 800 shares at the price of $70.00 back on Nov 11 ’24. After this action, Agarwal Vineet now owns 0 shares of Korro Bio Inc, valued at $56,000 using the latest closing price.
Agarwal Vineet, the Officer of Korro Bio Inc, proposed sale 800 shares at $70.00 during a trade that took place back on Nov 11 ’24, which means that Agarwal Vineet is holding shares at $56,000 based on the most recent closing price.
Stock Fundamentals for KRRO
The total capital return value is set at -0.41. Equity return is now at value -75.75, with -56.06 for asset returns.
Based on Korro Bio Inc (KRRO), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -2.11.
Currently, EBITDA for the company is -80.9 million with net debt to EBITDA at 0.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.28.
Conclusion
To sum up, Korro Bio Inc (KRRO) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
